14. Comparison 9. Bromocriptine versus placebo: global functioning.
Study | Outcome (instrument) | Experimental groupa (n = 9) | Control groupa (n = 9) | Statisticb | ||
Mean scores at baseline | Mean scores at endpoint | Mean scores at baseline | Mean scores at endpoint | |||
Powell 1995 | Global functioning (GAS‐high)c | 55.8 | 76.0 | 57.9 | 75.7 | Favours neither condition |
Powell 1995 | Global functioning (GAS‐low)c | 36.0 | 47.4 | 34.8 | 43.0 | Favours neither condition |
Powell 1995 | Global functioning (SCL‐90 GSI subscale)d | 0.8 | 0.4 | 0.8 | 0.7 | Favours neither condition |
GAS: Global Assessment Scale; GSI: Global Severity Index; SCL‐90: Symptom Check List‐90 |
aStandard deviations not reported bTrend‐over‐time analyses based on measurements at baseline and six months, with additional measurements at 2, 4, and 6 weeks, and then at 2, 3, 4, and 5 months; analyses conducted by trial investigators cHigh scores indicate better functioning dHigh scores indicate greater severity